niacinamide and melphalan

niacinamide has been researched along with melphalan in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19903 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Brown, DM; Brown, JM; Hirst, DG; Horsman, MR2
Everett, J1
Ali-Osman, F; Augustine, CK; Beasley, GM; Burchette, J; Jung, SH; McMahon, N; Padussis, J; Pruitt, SK; Selim, MA; Toshimitsu, H; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA1
Augustine, C; Beasley, GM; Brady, MS; Coleman, AP; Davies, MA; Peterson, BL; Raymond, A; Sanders, G; Selim, MA; Tyler, DS1

Trials

1 trial(s) available for niacinamide and melphalan

ArticleYear
A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.
    Annals of surgical oncology, 2012, Volume: 19, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Extremities; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Melanoma; Melphalan; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Array Analysis; Skin Neoplasms; Sorafenib; Tissue Distribution

2012

Other Studies

5 other study(ies) available for niacinamide and melphalan

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Changes in the response of the RIF-1 tumour to melphalan in vivo induced by inhibitors of nuclear ADP-ribosyl transferase.
    British journal of cancer, 1986, Volume: 53, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Body Temperature; Cell Survival; Dose-Response Relationship, Drug; Female; Leukocyte Count; Melphalan; Mice; Mice, Inbred C3H; Niacinamide; Nucleotidyltransferases; Poly(ADP-ribose) Polymerases; Sarcoma, Experimental; Time Factors

1986
Walker carcinosarcoma 256 in study of anticancer agents. II. Results.
    Cancer research, 1966, Volume: 26, Issue:8 Pt 2

    Topics: Acetates; Animals; Antineoplastic Agents; Azirines; Benzene; Benzoates; Butyrates; Carcinoma 256, Walker; Glycine; Mannitol; Mechlorethamine; Melphalan; Niacinamide; Oxides; Phthalic Acids; Pyridines; Rats; Sulfhydryl Compounds; Toluene; Xylenes

1966
Enhancement of melphalan cytotoxicity in vivo and in vitro by inhibitors of poly (ADP-ribose) polymerase.
    International journal of radiation oncology, biology, physics, 1984, Volume: 10, Issue:9

    Topics: Animals; Benzamides; Caffeine; Cell Line; Cell Survival; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Melphalan; Mice; Mice, Inbred C3H; NAD+ Nucleosidase; Neoplasm Transplantation; Neoplasms, Experimental; Niacinamide; Poly(ADP-ribose) Polymerase Inhibitors; Time Factors

1984
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:7

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Butadienes; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Melanoma; Melphalan; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Nude; Sorafenib; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays

2010